uniQure has built a world-class network of partners and collaborators.
uniQure collaborates with international pharmaceutical leaders, innovative early-staged companies as well as academic institutions and other research organizations to advance the company’s portfolio.
Bristol-Myers Squibb Company (NYSE:BMY) and uniQure announced in April 2015 an agreement that provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases as well as the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1 for Congestive Heart Failure.
uniQure has two agreements with Chiesi Farmaceutici, both of which were signed in April 2013. The first is for the commercialization of Glybera in Europe and other specified countries and the second is an agreement for the co-development and commercialization of uniQure's Hemophilia B program.
uniQure has a collaboration and license agreement with 4D Molecular Therapeutics, signed in January 2014, which is focused on the identification of novel optimized AAV variants that have greatly enhanced properties for achieving higher levels of gene expression. The collaboration will evolve AAV variants with greatly improved gene delivery properties in liver and the central nervous system.
In January 2015, we entered into a co-operation and license agreement with Synpromics Limited for the discovery of alternative small liver-specific promoters for sustainable and increased expression of larger therapeutic genes fitting the package capacity of AAV vectors.
Since 2012, uniQure has an agreement with the University of California San Francisco (UCSF) to develop a gene therapy product candidate for the treatment of Parkinson’s disease. UCSF is working with the National Institute of Health (NIH) to conduct a clinical trial of a gene therapy consisting of an AAV2 vector carrying the Glial cell line-derived neurotrophic factor, or GDNF gene.
In addition, uniQure collaborates with leading academic institutions and other research organizations that are sponsoring preclinical and early-stage clinical trials of gene therapy product candidates to which the company holds specified rights.
For more information about partnering and collaborating with uniQure, please contact:
Jonathan Garen, Chief Business Officer at j.garen@uniQure.com